bluuebunny/crossref_metadata_2025 huggingface dataset:
908-P: Predictive Model for Glycemic Level of People with Diabetes Mellitus Using Data Extracted from Electronic Medical Records in Primary Care
Authors: MISTRO SOSTENES , AGUIAR THALITA V.O. , CERQUEIRA VANESSA V. , SILVA KELLE O. , LOUZADO JOSÉ A. , KOCHERGIN CLAVDIAN N. , SOARES DANIELA A. , AMORIM WELMA W. , MEDEIROS DANIELLE S. , BEZERRA VANESSA M. , CARVALHO VIVIAN CARLA H. , AMARO EDSON , OLIVEIRA MÁRCIO G. , CORTES MATHEUS L.
Published: June 2020

Background: In Brazil, the use of electronic medical records in primary care has been expanding, improving the supply of information and data storage, and allowing the analysis of various aspects and prediction of future outcomes.

Aim: To develop a predictive model for the glycemic level of people with type 2 diabetes mellitus based on data from electronic medical records in primary care.

Methods: Data mining techniques were applied to choose response variables and potential predictors. Afterwards, data modelling was performed using Artificial Neural Networks (ANN), which are mathematical models inspired by the neural structure of intelligent organisms that acquire knowledge through experience. They detect non-linear relationships between the response variable and the explanatory variables without these variables having been defined.

Results: The highest probability of model accuracy was observed in the capillary blood glucose range between 100 and 300mg/dL. Model predictors and relative importance of each variable are shown in Figure 1.

Conclusion: Applying predictive modelling to data available in primary care electronic medical records can help the early identification of individuals with difficulty in glycemic control, and increase the efficiency in the allocation of efforts to treat diabetes.

Disclosure

S. Mistro: None. T.V.O. Aguiar: None. V.V. Cerqueira: None. K.O. Silva: None. J.A. Louzado: None. C.N. Kochergin: None. D.A. Soares: None. W.W. Amorim: None. D.S. Medeiros: None. V.M. Bezerra: None. V.H. Carvalho: None. E. Amaro: None. M.G. Oliveira: None. M.L. Cortes: None.

Funding

SUS Institutional Development Support Program; Brazil Ministry of Health; Israelite Hospital; Albert Einstein (25000.028646/2018-10); Medtronic Foundation
91-OR: CTRP3, a Novel Adipokine with Anti-inflammatory and Cardioprotective Properties, in Patients with Cardiovascular Diseases and Type 2 Diabetes Mellitus
Authors: KRATOCHVILOVA HELENA , KASPEROVA BARBORA JUDITA , LACINOVA ZDENKA , LANKOVA IVANA , TRNOVSKA JAROSLAVA , NETUKA IVAN , IVAK PETER , MAHRÍK JAKUB , HLAVÁCEK DANIEL , MRAZ MILOS , HALUZIK MARTIN
Published: June 2020

Cardiovascular diseases (CVD) are the most common cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). C1q TNF-related protein 3 (CTRP3) is a novel adipokine that reduces inflammation and acts cardioprotectively. The aim of our study was to analyze serum levels and gene expression of CTRP3 in subcutaneous and epicardial adipose tissue in patients with CVD and T2DM undergoing elective cardiac surgery.

38 patients with coronary artery disease (CAD) without T2DM (CAD group), 21 subjects with CAD and T2DM (T2DM group) and 18 patients with a valvular defect without CAD or T2DM (nonCAD group) were included into the study. Peripheral blood, subcutaneous (SAT) and epicardial adipose tissue (EAT) were examined at the start and end of elective cardiac surgery. mRNA expression was determined using qRT-PCR. 21 healthy subjects served as controls for serum CTRP3 (C group).

Baseline anthropometric and biochemical parameters were comparable in all groups except of higher fasting blood glucose (6.0±1.2 vs. 5.5±0.2 vs. 6.0±0.9 vs. 8.5±0.4 mmol/l for CAD vs. nonCAD vs. C vs. T2DM, p<0.001) and HbA1C (34.2±1.6 vs. 39.1±0.9 vs. 38.7±6.4 vs. 53.1±1.9 mmol/mol, p<0.001) in T2DM group. Compared to controls, all 3 CVD groups showed lower systemic CTRP3 concentrations (65.6±2.2 vs. 69.3±4.7 vs. 64.8±3.5 vs. 90.8±3.7 ng/ml for CAD vs. nonCAD vs. T2DM vs. C, p<0.001). In EAT, we found reduced mRNA expression of CTRP3 in T2DM compared to nonCAD group (0.61±0.27 vs. 6.61±2.33, p=0.005) and a similar, albeit non-significant trend in CAD group (1.55±0.32, p=0.132). Cardiac surgery resulted in a significant decrease in serum CTRP3 in all patients without affecting mRNA expression in EAT or SAT.

To conclude, decreased serum levels of CTRP3 in patients with CVD together with reduced mRNA expression in EAT in T2DM subjects with CAD indicate a possible role of CTRP3 in the pathogenesis of cardiovascular complications of type 2 diabetes mellitus.

Disclosure

H. Kratochvilova: None. B. Kasperova: None. Z. Lacinova: None. I. Lankova: None. J. Trnovska: None. I. Netuka: None. P. Ivak: None. J. Mahrík: None. D. Hlavácek: None. M. Mraz: None. M. Haluzik: Advisory Panel; Self; Lilly Diabetes, Sanofi. Consultant; Self; Ethicon US, LLC. Speaker’s Bureau; Self; AstraZeneca, Mundipharma International, Novartis AG, Novo Nordisk A/S.

Funding

Institute for Clinical and Experimental Medicine (00023001); RVOVFN64165; Ministry of Health of the Czech Republic (NV19-02-00118)
913-P: Higher Glucose Thresholds for Hypoglycemia Alarms on Continuous Glucose Monitoring Systems (CGMs) Are Associated with Less Time in Hypoglycemia in Patients with Impaired Awareness of Hypoglycemia
Authors: LIN YU KUEI , GROAT DANIELLE , CHAN OWEN , POP-BUSUI RODICA , VARNER MICHAEL , FISHER SIMON
Published: June 2020

A cross-sectional observational cohort analysis was conducted to assess whether higher hypoglycemia alarm thresholds on CGMs are associated with less hypoglycemia for both patients with normal (NAH) and impaired (IAH) awareness of hypoglycemia. Two-week CGM alarm/glucose data from 39 and 42 type 1 diabetes (T1D) patients with NAH and IAH (determined by the Clarke questionnaire) who have used CGMs for >3 months and had an active CGM usage time of ≥86% were included in the analysis. IAH patients with higher hypoglycemia alarm thresholds (i.e., alarm thresholds set >73 mg/dL vs. <73 mg/dL) spent 57.8% and 75.6% less time with glucose <70 and <54 mg/dL, respectively, while no significant differences were found between higher/lower alarm thresholds in the NAH groups. (Figure 1a, 1b) Fewer day and night-time numbers of hypoglycemic episodes (defined as ≥1 glucose value <70 and <54 mg/dL; Figure 1c, 1d) and shorter duration of episodes with glucose <54 mg/dL (Figure 1e, 1f) contributed to the reduced time spent in hypoglycemia in the IAH patients with higher alarm thresholds. The current analysis suggests that higher CGM hypoglycemia alarm thresholds are associated with less time spent in hypoglycemia in T1D patients with IAH, but not those with NAH.

Disclosure

Y. Lin: None. D. Groat: None. O. Chan: None. R. Pop-Busui: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc. Consultant; Self; Bayer Healthcare Pharmaceuticals Inc., Novo Nordisk Inc. Research Support; Self; AstraZeneca. Other Relationship; Self; American Diabetes Association. M. Varner: None. S. Fisher: None.

Funding

National Institute for Diabetes and Digestive and Kidney Diseases/Washington University School of Medicine (2P30DK020579); University of Utah Diabetes and Metabolism Research Center; National Institute for Diabetes and Digestive and Kidney Diseases (5T32DK091317); National Center for Advancing Translational Sciences (1ULTR002538)
937-P: Effects of Insulin and Exenatide on Glycemic Control and ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients with Severe Hyperglycemia
Authors: WU TSUNG-HUI , CHEN HARN-SHEN
Published: June 2020

Objective: To assess the efficacy of short-term insulin therapy compared with exenatide treatment on glycemic control, beta-cell function, insulin sensitivity, and long-term glycemic control in newly diagnosed type 2 diabetic patients with severe hyperglycemia.

Methods: Newly diagnosed type 2 diabetic patients with HbA1c above 9% were treated with intensive insulin injection for 10-14 days in the hospital or outpatient clinic. The oral glucose tolerance test (OGTT) was performed after intensive insulin treatment. After the OGTT, the patients were randomized to receive either insulin therapy (NPH injection twice daily) or exenatide therapy (exenatide injection twice daily) for further 4 months. The patients started to take oral antidiabetes drugs after 4 months of randomization. The OGTT was repeated 6 months after randomization to evaluateβ-cell function and insulin sensitivity again. The subjects were continually followed up for another 1 year to evaluate long-term glycemic control.

Results: We recruited 44 patients and 40 patients were randomized to insulin group (n = 22) and exenatide group (n = 18). The HbA1c level between insulin group and exenatide group at 6th month (6.74 ± 1.12% vs. 6.88 ± 0.76%; P = 0.681) and 18th month (6.60 ± 0.92% vs. 7.13 ± 0.83%; P = 0.093) of the study showed comparable results. The glucose area under the curve, insulinogenic index, and total insulin secretion improved significantly in both groups after 4 months of treatment. Compared with the exenatide group, the homeostasis model assessment of β-cell function index, insulinogenic index, and total insulin secretion were better in the insulin group.

Conclusions: A 4-month course of both the insulin and exenatide treatment could achieve good glycemic control in newly diagnosed type 2 diabetes with severe hyperglycemia. However, the insulin treatment could improve more β-cell function than exenatide therapy.

Disclosure

T. Wu: None. H. Chen: None.
94-OR: Postpartum Circulating MicroRNAs Can Predict the Development of Type 2 Diabetes in Women with Previous Gestational Diabetes
Authors: JOGLEKAR MUGDHA , WONG WILSON K. , EMA FAHMIDA KHAN , GEORGIOU HARRY M. , HARDIKAR ANAND , LAPPAS MARTHA
Published: June 2020

Type 2 diabetes (T2D) is a major cause of morbidity and death worldwide. Women with gestational diabetes mellitus (GDM) have a seven-fold higher risk of developing T2D later in life. However, accurate methods for post-partum T2D risk stratification of GDM women, are lacking. MicroRNAs are now well recognised as circulating biomarkers or mediators of metabolic disease. We aimed to determine if post-partum circulating microRNAs can predict the devolvement of T2D in women with previous GDM. Participants were part of the GDM follow-up program at the Mercy Hospital for Women, Australia. Plasma samples were collected at 12-week post-partum from 103 women following an index GDM pregnancy. Women were followed for 10 years to assess development of T2D. In a discovery approach, we measured 754 miRNAs in plasma from T2D non-progressors (N=11) and in T2D progressors (N=10) using TaqMan-based real time PCR on an OpenArray platform. Data were analysed using penalised logistic regression followed by bootstrapping. Top 15 miRNAs with high frequencies in this discovery bootstrap analysis were selected for validation in the remaining samples (N=82; 71 non-progressors and 11 progressors). Validation data were normalized to spike-in control (ath-miR-172a). Four miRNAs (miR-543, miR-410, miR-491 and miR-369-3p) were significantly dysregulated (p<0.05) between progressors and non-progressors to T2D, identifying these as risk factors. In a clinical model of prediction of T2D that included six traditional risk factors (age, BMI, pregnancy fasting glucose, post-OGTT change, cholesterol and triglycerides), the addition of these four circulating microRNA biomarkers measured at 12-weeks post-partum improved the prediction of future T2D from traditional AUC=0.8259 (95% CI: 0.68-0.9717) to an AUC= 0.9155 (95% CI: 0.8307-1). Replication of our findings in other cohorts is merited. Improved prediction will be beneficial in facilitating early intervention for T2D.

Disclosure

M. Joglekar: None. W.K. Wong: None. F. Ema: None. H.M. Georgiou: None. A. Hardikar: None. M. Lappas: None.
940-P: 14C-Tirzepatide ADME Studies in Rat and Monkey
Authors: MARTIN JENNIFER , CASSIDY KENNETH , CZESKIS BORIS , ALBERTS JEFF , LAO YANBIN , GLUFF JENNIFER , NIEDENTHAL ANDREA M.
Published: June 2020

Novel dual GIP and GLP-1 receptor agonist, tirzepatide (TZP), is being developed as a potential weekly treatment for type 2 diabetes (T2DM), weight management and nonalcoholic steatohepatitis. The absorption, metabolism and excretion of a single subcutaneous (SC) dose of 14C-tirzepatide was investigated in Sprague Dawley rat and cynomolgus monkey. In addition, tissue distribution of 14C-tirzepatide was assessed in quantitative whole-body autoradiography (QWBA) study in pigmented Long Evans rat following a single SC dose.

14C-Tirzepatide was prepared by incorporating four 14C’s in the mini-PEG linker between the peptide backbone and the di-acid chain to provide a specific activity of ∼ 40 µCi/mg. Following a single SC dose of 14C-tirzepatide in rat (3 mg/kg) and monkey (0.5 mg/kg), total radioactivity recovery was > 97% over the course of study (336 hours for rat and 672 hours for monkey). The dosed radioactivity was similarly excreted via urine and feces in rats and monkeys. Metabolism of 14C-tirzepatide was characterized in plasma and excreta. Parent drug was the major component in circulation accounting for approximately 87% of total radioactivity in rat and 84% in monkey. Tirzepatide was primarily metabolized via catabolism of the peptide backbone and β-oxidation of the di-acid chain.

Following a single SC dose of 14C-tirzepatide in rats (3 mg/kg), radioactivity was distributed to tissues as early as the first collection time point at 1-hour post dose. The tissues with the highest radioactivity concentrations were observed in the dose site, kidney, cecum, urinary bladder, intervertebral ligaments, arterial wall, lungs, and liver, generally at 12 to 48 hours post dose.

Disclosure

J. Martin: Employee; Self; Eli Lilly and Company. K. Cassidy: Employee; Self; Eli Lilly and Company. B. Czeskis: None. J. Alberts: Employee; Self; Eli Lilly and Company. Y. Lao: Employee; Spouse/Partner; Eli Lilly and Company. J. Gluff: None. A.M. Niedenthal: None.
951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM
Authors: ROBERTSON DARREN , HANSEN LARS , JAIN MEENA , PARKER VICTORIA , PETRONE MARCELLA , WANG TAO , HEISE TIM , JERMUTUS LUTZ
Published: June 2020

Background and Aims: Previously, cotadutide demonstrated significant glucose- and body weight-lowering effects in doses up to 300 µg. We examined the safety and efficacy of cotadutide in doses up to 600 µg in patients with T2DM.

Methods: In this double-blind, phase 2a study, 20 adults with T2DM (HbA1c ≤8.5%) were randomized to receive QD SC cotadutide (n=15) or placebo (n=5) for 77 days. A dose-escalation committee approved titrations >400 µg and ≤600 µg following a safety data review. Patients underwent continuous glucose monitoring.

Results: The adverse event profile suggests that the highest clinically tolerated dose has not been identified. Nausea was reported by 3 (20%) patients treated with cotadutide, with one episode of vomiting. There was a significant reduction from baseline in the 7-day average glucose levels (Figure). By day 77, 76.9% of patients in the cotadutide group achieved a >5% body weight loss. A significant reduction in least-squares mean from baseline in ALT level with cotadutide versus placebo was reported (-7.17 U/L, 90% CI: -12.21, -2.14).

Conclusions: Cotadutide was well-tolerated at doses up to 600 µg and reduced hyperglycemia, with clinically significant weight loss and beneficial effects on liver enzymes.

Disclosure

D. Robertson: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca. L. Hansen: Employee; Self; AstraZeneca. M. Jain: Employee; Self; CSL Behring. Stock/Shareholder; Self; AstraZeneca. M. Petrone: Employee; Self; AstraZeneca. T. Wang: Employee; Self; AstraZeneca. T. Heise: Advisory Panel; Self; Mylan, Novo Nordisk A/S. Research Support; Self; ADOCIA, Aerami, Becton, Dickinson and Company, Biocon, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Gan & Lee Pharmaceuticals, MedImmune, Merck KGaA, Mylan, Nordic Bioscience, Novo Nordisk A/S, Poxel SA, Sanofi, Xeris Pharmaceuticals, Inc., Zealand Pharma A/S. Speaker’s Bureau; Self; Eli Lilly and Company, Novo Nordisk A/S. L. Jermutus: Employee; Self; AstraZeneca. Stock/Shareholder; Self; AstraZeneca.

Funding

AstraZeneca
969-P: Effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes
Authors: OHWAKI KENJI , FURIHATA KENICHI , OURA TOMONORI , IMAOKA TAKESHI
Published: June 2020

Dual GIP and GLP-1 receptor agonist, tirzepatide (TZP), showed clinically meaningful HbA1c reduction and dose-dependent weight loss in Japanese patients with type 2 diabetes in an 8-week, Phase 1, multiple ascending dose study. Decreased appetite was the most frequently reported treatment-emergent adverse event, with nearly half of TZP-treated patients experiencing decreased appetite without nausea or vomiting. We explored the effects of TZP 5 mg, 10 mg, and 15 mg on meal intake and appetite sensation in these patients. Standardized lunch and dinner meals were provided on Days -1, 2 and 51 (700 kCal; 20% protein, 25% fat, 55% carb). Amount (%) of meals consumed were recorded. Subjective ratings of appetite sensations were measured by a 100-mm visual analogue scale for parameters of hunger, fullness, satiety, and prospective food consumption pre- and 4-5h post-meal. Meal intake decreased on Day 2 (TZP 5 mg) and dose-dependently decreased with TZP vs. PBO on Day 51 (Figure). The proportion of meal occasions with ≥50% meal leftover was 0% (PBO) and 16.7% (TZP 5 mg) on Day 2 and 0% (PBO), 13.6% (TZP 5 mg), 18.2% (TZP 10 mg) and 30.0% (TZP 15 mg) on Day 51. There was a trend in decreasing hunger and fullness scores with all TZP doses vs. PBO on Day 51. However, satiety, prospective food consumption and overall appetite scores did not differ among groups. TZP dose-dependently reduced meal intake and demonstrated a trend in decreased hunger.

Disclosure

K. Ohwaki: Employee; Self; Eli Lilly Japan K.K. K. Furihata: None. T. Oura: Employee; Self; Eli Lilly Japan K.K. Stock/Shareholder; Self; Eli Lilly and Company. T. Imaoka: Employee; Self; Eli Lilly Japan K.K.

Funding

Eli Lilly and Company
979-P: Improved Technology Satisfaction and Sleep Quality with Medtronic Minimed Advanced Hybrid Closed-Loop Delivery Compared with Predictive Low Glucose Suspend in People with Type 1 Diabetes in a Randomized Crossover Trial
Authors: COLLYNS OLIVIA , MEIER RENEE , BETTS ZARA , CHAN DENNIS , FRAMPTON CHRIS , FREWEN CARLA M. , GALLAND BARBARA , HEWAPATHIRANA NIRANJALA , JONES SHIRLEY , KURTZ NATALIE , SHIN JOHN , VIGERSKY ROBERT , WHEELER BENJAMIN J. , DE BOCK MARTIN
Published: June 2020

Background: Automated insulin delivery aims to lower treatment burden and improve quality of life as well as glycemic outcomes.

Methods: This dual-centre, randomized, open-label, two-sequence cross-over study in automated insulin delivery naïve users, compared Medtronic Minimed® Advanced Hybrid Closed Loop (AHCL) to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP+PLGM). At the end of each 4 week intervention impacts on quality of life were compared using age-appropriate scales: Diabetes Treatment Satisfaction Questionnaire status and change (DTSQs and DTSQc), Diabetes Technology Questionnaire (DTQ), Pittsburgh Sleep Quality Index (PSQI), World Health Organisation-Five Well-Being Index (WHO-5), Hypoglycemic Fear Survey (HFS-II) and Hypoglycemia Confidence Scale (HCS).

Results: 59/60 people completed the study (mean age 23.3±14.4yrs). Statistically significant differences favouring AHCL were demonstrated in several scales (data shown as mean±SE). Technology satisfaction favoured AHCL over PLGM as shown by a higher score in the DTSQs during AHCL (n=28) vs. SAP+PLGM (n=29) (30.9±0.7 vs. 27.9±0.7, p=0.004) and DTSQc AHCL (n=29) vs. SAP+PLGM (n=30) (11.7±0.9 vs. 9.2±0.8, p=0.032) in adults. Adolescents also showed a higher DTSQc score during AHCL (n=16) vs. SAP+PLGM (n=15) (14.8±0.7 vs. 12.1±0.8, p=0.024). The DTQ “change” score (n=59) favoured AHCL over SAP+ PLGM (3.5±0.0 vs. 3.3±0.0, p<0.001). Improved sleep quality was demonstrated by the lower PSQI in those aged over 16 years (n= 36) during AHCL vs. SAP+PLGM (4.8±0.3 vs. 5.7±0.3, p=0.048) with > 5 indicating poor quality sleep. No differences were found in the other scales.

Conclusion: The findings from this RCT suggest AHCL compared to SAP + PLGM mode has the potential to increase treatment satisfaction and improve subjective sleep quality in adolescents and adults with T1D.

Disclosure

O. Collyns: None. R. Meier: None. Z. Betts: None. D. Chan: None. C. Frampton: None. C.M. Frewen: None. B. Galland: None. N. Hewapathirana: Other Relationship; Self; Sanofi. S. Jones: None. N. Kurtz: Employee; Self; Medtronic. J. Shin: Employee; Self; Medtronic. R. Vigersky: Employee; Self; Medtronic. B.J. Wheeler: Research Support; Self; Medtronic. M. de Bock: None.
988-P: Do-It-Yourself Artificial Pancreas Systems for Type 1 Diabetes Reduce Hyperglycemia without Increasing Hypoglycemia
Authors: ZABINSKY JENNIFER , HOWELL HALEY , GHEZAVATI ALIREZA , LEWIS DANA M. , NGUYEN ANDREW , WONG JENISE C.
Published: June 2020

Background: Patient-driven innovation has led to the development of do-it-yourself artificial pancreas systems (DIYAPS) for the management of type 1 diabetes (T1D). There have been few studies comparing glycemic outcomes for DIYAPS compared to conventional sensor-augmented pump (SAP) therapy.

Methods: A retrospective double cohort study was performed. The DIY group consisted of people with T1D using DIYAPS (OpenAPS, Loop, and AndroidAPS) who contributed data to the OpenAPS Data Commons. The SAP group included age-matched SAP users whose sensor data was obtained through the Tidepool Big Data Donation Project. The primary outcome of percent of sensor glucoses (SG) in low glucose range (<70 mg/dL) was determined for both groups and compared. Secondary outcomes included mean SG, number of >=15-minute hypoglycemic episodes (<70 mg/dL) per month, and percent of SG in high glucose range (>=180 mg/dL) and in target range (70-180 mg/dL).

Results: The DIY group included 90 days of data from 74 individuals with mean age of 36 ± 15 years and 24 ± 16 years since T1D diagnosis. The SAP group had 98 individuals with mean age of 35 ± 14 years and 20 ± 13 years since diagnosis. There was no significant difference in percent of SG <70 mg/dL between the two groups (3.8% for DIY vs. 4.7% for SAP, p=0.17). There was also no difference in number of hypoglycemic episodes per month (32.9 for DIY vs. 33.4 for SAP, p=0.87) or in percent of SG <54 mg/dL (0.8% for DIY vs. 1.3% for SAP, p=0.09). Mean SG was lower for the DIY group (134.9 ± 19.1 mg/dL for DIY vs. 150.3 ± 25.7 mg/dL for SAP, p<0.0001). Percent of SG >=180 mg/dL was lower (16.9% for DIY vs. 26.1% for SAP, p<0.0001) and percent in target glucose range was greater for the DIY group (79.3% for DIY vs. 69.2% for SAP, p<0.0001).

Conclusion: Users of DIYAPS had a comparable amount of hypoglycemia to those using SAP and had less hyperglycemia. This study suggests that the glycemic benefit of DIYAPS is in reducing hyperglycemia without compromising the low occurrence of hypoglycemia.

Disclosure

J. Zabinsky: None. H. Howell: None. A. Ghezavati: None. D.M. Lewis: Research Support; Self; JDRF. A. Nguyen: None. J.C. Wong: Consultant; Self; pH Pharma. Research Support; Self; Dexcom, Inc.

Funding

JDRF
990-P: Inhaled and Background Basal Insulins Improved A1C and QoL Subdomains in Patients with Type 2 Diabetes: An Observational Study
Authors: KIPNES MARK , SALHIN AMNA , RYAN TERRI , VADAKEKALAM JACOB , PAMAR VIJAYVEER , TRIGOSO FERNANDO , AKHRASS FIRAS
Published: June 2020

Rapid-acting inhaled (Afrezza) and injected mealtime insulins are available for patients with type 2 diabetes who are also treated with basal insulin. In this interim analysis of a single-site, observational, investigator initiated study, time spent in glycemic goal range (70-180 mg/dL) without significant hypoglycemia (primary endpoint) was assessed in the intent-to-treat population of patients with type 2 diabetes (N=25; 60%M; age 62y; wt 95.7±4.4kg; A1c 8.3±0.2%). Patients were titrated from pre-meal insulin plus basal insulin to inhaled insulin plus basal insulin over 2 weeks and followed for 14 weeks. At Week 14, mean (±SE) times spent above (>180 mg/dL; -1.7±3.2 mins; P=0.60), in (70 180 mg/dL; -1.2±2.6 mins; P=0.65), and below (<70 mg/dL; +2.9±2.5 mins; P=0.26) glycemic goal range were not significantly different from baseline. However, A1c significantly decreased from baseline at Week 14 (-0.76%±0.18; P=0.0002). At Week 14, Quality of Life (QoL) Total score did not significantly change from baseline (+0.19±0.13; P=0.15). However, Useful (+0.46±0.20; P=0.03), Freeing (+0.92±0.24; P=0.0008), and Difficult ( 0.68±0.28; P=0.02) QoL subdomains significantly improved from baseline at Week 14. There were no deaths, no serious hypoglycemic events, but 4 patients discontinued (3 upper respiratory tract, 1 diarrhea). Five patients experienced cough, 2 patients chest mucus/congestion, and 2 patients cough/chest congestion. Most upper respiratory events were associated with use of >60 units/day inhaled insulin. Although this interim analysis did not achieve its primary endpoint of significant increase of time spent in glycemic goal range, possibly caused by patients not self-adjusting post-prandial dosing as instructed. Patients treated with inhaled insulin with background basal insulin for 14 weeks experienced significant reduction of A1c and significant improvements of Useful, Freeing, and Difficult QoL subdomains compared to baseline.

Disclosure

M. Kipnes: None. A. Salhin: None. T. Ryan: None. J. Vadakekalam: None. V. Pamar: None. F. Trigoso: None. F. Akhrass: None.

Funding

MannKind Corporation
992-P: Patient-Reported Outcomes for 2,335 Adults with Type 2 Diabetes Using the Omnipod Insulin Management System Show Glycemic Improvement over First 90 Days of Use
Authors: CARLSON ANDERS L. , HUYETT LAUREN M. , JANTZ JAY , CHANG ALBERT , VIENNEAU TODD , LY TRANG T.
Published: June 2020

Patient-reported outcomes are a useful tool to understand the impact of treatments in clinical application on a large scale. This retrospective study characterized patient-reported outcomes of a large cohort of adults in the United States with type 2 diabetes using a tubeless insulin pump (Omnipod® or Omnipod DASH™ Insulin Management System, Acton, MA). From Jan. 2015-Jan. 2020, patient-reported outcomes were recorded before and ≥90 days after initiating system use. Primary outcomes were change in self-reported A1C and total daily dose of insulin.

Patients (N=2,335) were aged (mean±SD) 58±11y and 53% female. The percentage of users with a self-reported A1C ≤8% increased from 33% pre-tubeless pump to 64% post-tubeless pump, and the percentage with a self-reported A1C >9% decreased from 44% to 15% (p<0.001, Table). Self-reported A1C decreased from 9.2±2.7% to 7.9±2.2% (p<0.001). The self-reported total daily insulin for those with data available (n=2,130) was 33±49 U/d lower on average from pre-tubeless pump to post-tubeless pump, from 104±68 U/d to 71±40 U/d (p<0.001).

These patient-reported outcomes provide positive evidence that use of a tubeless insulin pump was associated with glycemic outcomes that exceed U.S. National Healthcare Effectiveness Data and Information Set (HEDIS) standards for adequate diabetes management.

Disclosure

A.L. Carlson: Consultant; Self; Medtronic. Research Support; Self; Abbott, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk A/S, Sanofi, UnitedHealth Group. L.M. Huyett: Employee; Self; Insulet Corporation. J. Jantz: Employee; Self; Insulet Corporation. A. Chang: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. T.T. Ly: Employee; Self; Insulet Corporation.

Funding

Insulet Corporation
996-P: A Randomized Study to Evaluate the Efficacy of Insulclock Pen Device in Insulin-Treated Patients with Uncontrolled Type 2 Diabetes
Authors: RAMOS CLEMENTINA , GALINDO RODOLFO J. , ALAM MUHAMMAD M. , CARDONA SAUMETH , ALBURY BONNIE S. , OLADEJO OMOLADE , PASQUEL FRANCISCO J. , VELLANKI PRIYATHAMA , FAYFMAN MAYA , MIGDAL ALEXANDRA , DAVIS GEORGIA , HAW JEEHEA SONYA , UMPIERREZ GUILLERMO E.
Published: June 2020

Insulin pen devices have been reported to improve patient satisfaction and treatment adherence compared to the traditional vial/syringe. Insulclock® is a small electronic device plugged onto insulin pen to track information via Bluetooth to smart-phone technology on date, time and dosage of injections and with an alarm system to reduce insulin omissions. We performed a randomized, cross-over design study in patients with type 2 diabetes (T2D) on basal insulin to assess the efficacy and satisfaction of Insulclock device. Eighty T2D patients on basal insulin ± oral agents with HbA1c between 7.0% and 12.0% were randomized to a 12-week ’intervention’ phase receiving reminders or to a 12-week ’control’ phase with device without feedback. Basal insulin was titrated every 2 weeks to a target fasting and premeal glucose between 70-130 mg/dl. Study outcomes included differences between groups on glycemic control, treatment adherence and satisfaction (DTSQc survey).

Baseline characteristics were similar between groups (56±11 years, HbA1c 9.2%±1.5). HbA1c improved significantly from baseline, with reduction of 0.9 % in the intervention and 0.7% in the control group. Insulclock improved glycemic control with an estimated reduction in average mean daily blood glucose (BG), fasting BG, and pre-meal BG of 6.03 (95% CI: [-3.21, 15.3]), 6.66 (95% CI: [-1.72, 15.04]), and 5.57 (95% CI: [-6.15, 17.31]) mg/dl, respectively. Repeated measures analyses based on linear mixed models suggest significant effects of insulclock on the trajectory of mean daily BG, fasting BG, pre-meal BG (p<0.01, p=0.03, p=0.01). There were no differences in treatment adherence or on the rate of hypoglycemia, and patients were equally satisfied with the device during intervention and control phase (DTSQc 15.5±3.7 and 15.2±3.1, respectively).

In conclusion, the use of Insulclock resulted in improved glycemic control and treatment satisfaction in insulin treated patients with T2D.

Disclosure

C. Ramos: None. R.J. Galindo: Advisory Panel; Self; Lilly Diabetes. Consultant; Self; Valeritas, Inc. Research Support; Self; Novo Nordisk Inc. Other Relationship; Self; UpToDate. M.M. Alam: None. S. Cardona: None. B.S. Albury: None. O. Oladejo: None. F.J. Pasquel: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. Research Support; Self; Dexcom, Inc., Merck Sharp & Dohme Corp., National Institutes of Health. P. Vellanki: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc. M. Fayfman: None. A. Migdal: None. G. Davis: None. J. Haw: None. G.E. Umpierrez: None.
997-P: Testing a Novel Infusion Set for Extended Wear Duration
Authors: BUCKINGHAM BRUCE A. , MARCAL TATIANA , HOFFMAN LANCE , MUSOLINO GIANLUCA , EKHLASPOUR LAYA , ZHANG GINA , CHATTARAJ SARNATH
Published: June 2020

This was a randomized double blinded study of a novel infusion set with and without heparin, hypothesizing that small doses of heparin would decrease thrombosis and subcutaneous inflammation.

The MiniMed™ Quick-set™ infusion set was modified with a new tubing connector from current P-Cap. The P-Cap was modified to contain a foam (F) or a foam with heparin (F+H) connector. Visibly the sets appeared identical. Each participant wore two F and two F + H sets for 7 days or until set failure. The order of infusion set wear was randomly assigned. Infusion set failure was determined by unexplained hyperglycemia >250mg/dL with a failed correction dose, ketones >0.6mmol/L, evidence of infection, occlusion alarms, or adhesive failure. Infused set survival was compared to similar published 1-week studies using standard Quick-sets.

There were 20 participants (mean age 29.5±8 years). Each set was worn 40 times. Length of wear and causes of failure are shown below. Length of wear was not different between the F and F+H groups, but both had improved length of wear compared to historical Quick-sets (p<0.05). There was no significant increase in insulin requirements or mean glucose values throughout the seven days of wear in any group.

There was no difference in overall duration of wear between the F and F+H groups. Both infusion set groups intended for extended wear had significantly better survival than the historical Quick-Set™ group. Further studies are planned with the F group.

Disclosure

B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Medtronic. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. T. Marcal: None. L. Hoffman: None. G. Musolino: None. L. Ekhlaspour: None. G. Zhang: None. S. Chattaraj: Employee; Self; Medtronic.

Funding

Medtronic Diabetes
The regulation of glycemia in the recovery phase after stroke counteracts the detrimental effect of obesity-induced type 2 diabetes on neurological recovery
Authors: Admin Ada , Augestad Ingrid Lovise , Pintana Hiranya , Larsson Martin , Krizhanovskii Camilla , Nyström Thomas , Klein Thomas , Darsalia Vladimer , Patrone Cesare
Published: June 2020

The interplay
between obesity and T2D in post-stroke recovery is unclear. Moreover,
the impact of glucose control during the chronic phase after stroke is undetermined.

We investigated whether
obesity-induced T2D impairs neurological recovery after stroke by using a
clinically relevant experimental design. We also investigated the potential
efficacy of two clinically-used T2D drugs: the dipeptidyl peptidase-4 inhibitor
linagliptin and the sulfonylurea glimepiride.

We induced transient middle cerebral artery occlusion
(tMCAO) in T2D/obese mice (after 7 months of high-fat diet (HFD)) and
age-matched controls. After stroke, we replaced HFD with standard diet for 8
weeks to mimic the post-stroke clinical situation. Linagliptin or
glimepiride were administered daily from 3 days after tMCAO for 8 weeks. We
assessed neurological recovery weekly by
upper-limb grip strength. Brain damage, neuroinflammation, stroke-induced
neurogenesis and atrophy of parvalbumin (PV)+ interneurons were quantified by
immunohistochemistry.

T2D/obesity impaired post-stroke neurological recovery in association
with hyperglycemia, neuroinflammation and atrophy of PV+
interneurons. Both drugs counteracted these effects. In non-diabetic mice, only
linagliptin accelerated recovery.

These
findings shed light on the interplay between obesity
and T2D in stroke recovery. Moreover, they promote
the use of rehabilitative strategies based on efficacious glycemia regulation, even
if initiated days after stroke.
TEKNIK MASSAGE EFFLURAGE DAPAT MENGURANGI NYERI KALA I PADA IBU BERSALIN DI PUSKESMAS HALMAHERA KOTA SEMARANG
Authors: Rahayu Sri
Published: June 2020

Pada tahun 2018 didapatkan data di Kota Semarang jumlah persalinan 25.150 per-kelahiran hidup, dan pada bulan Januari – Agustus 2019 jumlah persalinan di puskesmas Halmahera berjumlah 234 orang. Salah satu pelayanan selama persalinan adalah pengurangan nyeri kala I dengan Massage Efflurage. Tujuan penelitian untuk mengetahui manfaat teknik massage Efflurage terhadap pengurangan nyeri kala I pada ibu bersalin di puskesmas Halmahera Tahun 2019. Jenis penelitian survey dengan desain penelitian metode pre-eksperimen dengan pendekatannya onegroup pra-post test design. Sampelnya ibu bersalin di puskesmas Halmahera pada bulan September - November 2019 berjumlah 68 orang secara Accidental Sampling. Analisisnya uji Normalitas Saphiro-Wilk dan uji Wilcoxon didapatkan hasil sebelum massage efflurage responden mengalami nyeri sedang setelah massage efflurage menjadi nyeri ringan berjumlah 55 (80,9%), sebelum massage efflurage responden mengalami nyeri berat setelah massage efflurage menjadi nyeri ringan berjumlah 4 (5,9%) dan sebelum massage efflurage responden mengalami nyeri berat setelah massage efflurage menjadi nyeri sedang berjumlah 9 (13,2%). Jadi pada Uji Wilcoxon teknik massage efflurage sangat bermanfaat terhadap pengurangan nyeri kala I ibu bersalin di puskesmas Halmahera Tahun 2019 dengan p=0.00. Sarannya pada asuhan kebidanan dengan manajemen nyeri pada persalinan dengan massage efflurage dapat dijadikan suatu intervensi dalam manajemen sensasi nyeri persalinan pada asuhan  sayang ibu.
POTENSI CEMARAN BAKTERI Escherichia coli PADA LIMBAH CAIR RUMAH POTONG AYAM (RPA) TERHADAP LINGKUNGAN DI KOTA MAGELANG
Authors: Syarifuddin Alfian , Yuliastuti Fitriana , Pradani Missya Putri Kurnia
Published: June 2020

Kualitas air secara biologis ditentukan oleh banyak parameter, antara lain parameter mikroba pencemar/ patogen. Bakteri Escherichia coli merupakan salah satu bakteri yang menjadi salah satu parameter kualitas suatu air. Jumlah kasus diare di Kota Magelang tahun 2014 mengalami kenaikan dibanding kasus diare tahun 2013, yaitu sebanyak 3.577 kasus dengan persentase sebesar 139,59% yang disebabkan oleh bakteri. Penelitian ini dilakukan untuk mengetahui ada tidaknya cemaran bakteri Escherichia coli dan mengetahui nilai Angka Lempeng Total (ALT) cemaran bakteri Escherichia coli pada air bilasan pada Rumah Potong Ayam (RPA) yang dapat berpotensi sebagai pencemar di lingkungan Kota Magelang. Metode yang digunakan dalam penelitian ini adalah cawar sebar dengan menggunakan media untuk pengujian adalah media TBX agar. Hasil penelitian menunjukkan adanya cemaran bakteri Escherichia coli yang melebihi 1x101CFU/ml pada air bilasan ayam pada beberapa RPA di Kota Magelang, yaitu 61,1% sampel uji atau sekitar 11 tempat sampling dari total sebanyak 18 tempat pemotongan ayam. Hasil tersebut menunjukkan bahwa air hasil bilasan tersebut dapat berpotensi sebagai salah satu sumber cemaran bakteri Escherichia coli pada daging ayam dan air tanah lingkungan sekitar pembuangan limbah air bilasan. Hanya terdapat 38,9% dari 18 RPA masih memenuhi ambang batas cemaran bakteri Escherichia coli. Oleh karena itu, perlu adanya langkah-langkah strategis berikutnya, yaitu pengolahan air limbah RPA dengan proses biofilter, serta dapat disosialisasikan terkait cara mengolah daging yang benar.
EVALUASI AKHIR GALUR HARAPAN KACANG PANJANG (Vigna sesquipedalis L. Fruwirth) POLONG UNGU
Authors: Zulfarosda Ratna , Damanhuri Damanhuri , Waluyo Budi , Kuswanto Kuswanto
Published: June 2020

A Final Evaluation Of Expected Lines Of Yardlong Bean (Vigna sesquipedalis L. Fruwirth)  With Purple Pods. Evaluation toward expected lines yardlong bean purple pod ability conducted to obtain lines which have superiority in yield, yiled components and other traits. Evaluation was done by analyzed adaptation and stability test. Research towards 6 lines was conducted at 6 different locations based on altitude (the middle land and low land), condition areas (rainfall and temperature) as well as the conditions of cultivation (with and without mulch application). Adaptation and stability test provides information related to lines response of environmental condition for recommended cultivation on specific or all types environment. The results showed superiority pod weight per hectare of BU 1 (9,18 t ha-1) followed by BU 6 (8,81 t ha-1) and BU 4 (6,88 t ha-1). Those lines were broadly adaptive for all types of environments. Lines that adaptive in spesific environment, BU 2 (8,03 t ha-1) produced optimal yield on marginal environment, while BU 5 (10,03 t ha-1) adaptive at productive environment. Based on lines description, all lines have superiority of purple pod colored and specifically BU 3 had highest anthocyanins content.
ANALISIS PERTUMBUHAN, ASIMILASI BERSIH DAN PRODUKSI TERUNG (Solanum melongena L.): DOSIS PUPUK KANDANG KAMBING DAN PUPUK NPK
Authors: Zulkifli Tengku Boumedine Hamid , Tampubolon Koko , Nadhira Ahmad , Berliana Yunida , Wahyudi Erfan , Razali Razali , Musril Musril
Published: June 2020

Growth, Net Assimilation and Yield Analysis of Eggplant(Solanum melongena L.): Dosage of Goat Manure and NPK FertilizerThe research was aimed to obtain the dose of goat manure, NPK fertilizer and the interaction in increasing the growth and yield of eggplant. The research was usedthe randomized block design factorial with the first factor (goat manure) such as K0= 0 ton.ha-1, K1= 10 ton.ha-1, K2= 20 ton.ha-1 and the second factor (NPK Mutiara 16-16-16) such as P0= 0 ton.ha-1, P1= 100 ton.ha-1, P2= 200 ton.ha-1, P3= 300 ton.ha-1 with three replications. This research was conducted at Jl. Eka Rasmi, Medan Johor Subdistrict, Medan, North Sumatra from August until October 2019. The parameters such as plant height, leaf area, fresh weight of root and shoot, dry weight of root and shoot, total dry weight, fruitweight.plant-1, fruit weight.plot-1, crop growth rate (CGR), relative growth rate (RGR), and net assimilation rate (NAR) wereanalyzed using the ANOVA and the means were followed by DMRT test at the level of 5% used the IBM SPSS Statistics v.20. The results showed an increase in leaf area, fresh weight of shoot, dry weight of root, dry weight of shoot, total dry weight, and fruit weight.plant-1, of eggplant plant with the increasing dose of goat manure up to 20 ton.ha-1of 23.27%; 35.85%; 17.64%; 16.55%; 16.66%; and 17.18%, respectively compared to untreated except plant height. Growth in leaf area, fresh weight of shoot, dry weight of root, dry weight of shoot, total dry weight, fruit weight.plant-1 and fruit weight.plot-1of eggplant plant were increased with increasing NPK fertilizer dosage up to 300 kg.ha-1of 16.88%; 25.96%; 24.08%; 38.37%; 34.46%; 21.85%; and 19.22%, respectively compared to untreated. The interaction of goat manure with NPK does not significantly affect on the growth and yield of eggplant plant. The CGR, RGR, and NARvalue in the giving of goat manure from 10 until 30 days after planting was higher compared to the application of Mutiara NPK fertilizer.
PENGARUH SISTEM OLAH TANAH DAN PEMUPUKAN NITROGEN JANGKA PANJANG TERHADAP RESPIRASI TANAH DI LAHAN POLITEKNIK NEGERI LAMPUNG TAHUN TANAM KE-27
Authors: Damayanti Erdiana , Utomo Muhajir , Niswati Ainin , Buchari Henrie
Published: June 2020

Unsustainable cultivation techniques can cause carbon loss on farm.   The cultivation technique that is often used by farmers today is intensive tillage.  Intensive tillage can increase CO2. Steps to reduce CO2 gas emissions, while increasing carbon stored in the soil by implementing agricultural cultivation with conservation tillage system (Olah Tanah Konservasi). The conservation tillage system is able to reduce global warming through absorption of C in the soil, and reduce CO2 emissions. In addition, fertilization can also affect CO2 emissions. CO2 emissions in the soil come from soil respiration. The purpose of this study was to determine the effect of long-term tillage systems on soil respiration, determine the effect of long-term N fertilization on soil respiration, and determine the effect of interactions between tillage systems and long-term N fertilization on soil respiration. The study was arranged in a randomized block design (RBD) consisting of two factors, namely the tillage system and nitrogen fertilization factors. The first factor is the treatment of tillage system (T) namely T0 = no tillage, and T1 = intensive tillage, while the second factor is without nitrogen fertilizer (N0) and high nitrogen fertilizer (N1). The data obtained will be tested for homogeneity by Bartlett Test and additives tested by Tukey Test. Furthermore, the data were analyzed by analysis of variance and continued with a BNJ test of 5% level. Observation of soil respiration was done 4 times, namely -1, 1, 2, 3 days after tillage. The results showed that soil respiration one day before to three days after the soil was treated in intensive tillage (OTI) was the same as the no tillage system (TOT), soil respiration -1 days after tillage to 3 days after tillage on nitrogen fertilization (100 N kg ha-1 ) given in the previous planting season the same as without fertilization (0 kg N ha-1), and there is no interaction between the tillage system and nitrogen fertilization on soil respiration.
UJI KEMAMPUAN ISOLAT JAMUR Trichoderma spp. SEBAGAI ANTAGONIS Ganoderma boninense DAN PLANT GROWTH PROMOTING FUNGI (PGPF)
Authors: Yogaswara Yohan , Suharjo Radix , Dirmawati Suskandini Ratih , Ginting Cipta
Published: June 2020

This study aims to determine the ability of Trichoderma spp. Isolate that collection of Biotechnology Laboratory, Faculty of Agriculture, University of Lampung as an antagonist againstGanoderma boninense and also its ability as a Plant Growth Promoting Fungi (PGPF). Testing of Trichoderma spp. as an antagonist include tests for growth, spore density, and viability. Testing of Trichoderma spp. as PGPF (Plant Growth Promoting Fungi) using cucumber plants F1 variety to obtain the ability of Trichoderma spp. in improving cucumber plant performance. The data obtained were analyzed by analysis of variance and further tested DMRT (Duncan's Multiple Range Test) at 5% level. The results showed that all isolates of Trichoderma spp.  can act as an antagonist againstGanoderma boninense. In the PGPF test, there were 3 isolates of Trichoderma spp. which showed the best performance as a plant growth promoting namely  L1, L5 and L10 isolates.  In addition, these isolates also have good antagonistic.
PENGARUH LAMA SIMPAN PADA VIGOR BENIH DAN KECAMBAH SORGUM (Sorghum bicolor [L.] Moench) GENOTIPE KAWALI DAN P/F-10-90A
Authors: Anggraini Iska Hartina , Kamal Muhammad , Pramono Eko , Setiawan Kukuh
Published: June 2020

Sorghum is a type of carbohydrate-producing serelia plant. Sorghum has a great potential to be developed in Indonesia.  Seed storing time is the time period of the seed storage before the seed is planted again, while the storage of the seed is carried out with the aim of maintaining seed viability in the save period for as long as possible and can be used for the next planting period.  The purpose of this study was to determine the effect of storage time on seed vigor and sprouts of Kawali and P/F-10-90A genotypes. This research was conducted at the Laboratory of Seed and Plant Breeding, Faculty of Agriculture, University of Lampung, Bandar Lampung which runs from February 2017 until February 2018. This study uses split plot design with 3 group replications. The main plot is the storage time (LS) that was consisted of 0, 4, 8 and 12 months storage time period. Subplot is genotype (G), which consists of Kawali (G1 ) and P / F-10-90A (G2). The results showed that seed vigor and sprouts decreased significantly at 4 and 8 months storage time with the percentage of dead seeds 16.7% and 40.7%, while the percentage of normal strong sprouts at 4 months amounted to 74% for genotype P/ F-10-90A  and 8 months 54% for genotype Kawali.  P/F-10 -90A genotypes have higher seed vigor and sprouts vigor compared to Kawali genotypes as indicated by dead seed variables, strong normal sprouts, normal sprout length canopy, long root primary roots, normal sprouts, dry weight normal sprouts, and normally strong sprouts. The effect of interaction  between storage time and genotype was shown by seed vigor of genotype P/F-10-90-A seedlings which were proven to be superior for 4, 8 and 12-month storage time period.  Excellence of genotype P/F-10-90-A make it can be stored and was allowed to be used as good seed on next season farming.